

10771557



Approved for use through 07/31/2008. OMB 0701-0001  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet		2	of	2	Attorney Docket Number		000166.0109-US02
-------	--	---	----	---	------------------------	--	------------------

Complete If Known	
Application Number	Divisional of 10/268,059
Filing Date	February 5, 2004
First Named Inventor	David Edwards
Art Unit	N/A
Examiner Name	Not Yet Assigned

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (If known)				
KM	BA	BA-0 407 276-A2 GP	01/1991	VALOIS Societe Anonyme d'ite		
↓	BB	EP-0 508 292-A1	09/1992	Rhone-Poulenc Rorer Limited		
↓	BC	WO-WO 94/08552-A2	04/1994	Medkalski et al.		
↓	BD	WF-WO 00/64519-A1	11/2000	Halkarainen et al.		
KM	BE	WO-WO 01/07107	02/2001	Pharmaceutical Discovery Corporation		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Code of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<div>KM</div> <div>↓</div> <div>↓</div> <div>↓</div> <div>↓</div> <div>↓</div> <div>↓</div> <div>↓</div> <div>↓</div> <div>KM</div>	CA	Blagaard, H. et al., Fine particle mass from the Diskus Inhaler and Turbuhaler Inhaler in children with asthma, European Respiratory Journal, 11: 1111-1115 (May 1998).	
	CB	de Boer, A.H. et al., "Inhalation characteristics and their effects on in vitro drug delivery from dry powder Inhalers, Part 1. Inhalation characteristics, work on breathing and volunteers' preference in dependence of the inhaler resistance," International Journal of Pharmaceutics 130: 231-244 (1996).	
	CC	Dunbar, Craig A. et al., A Comparison of Dry Powder Inhaler Dose Delivery Characteristics Using a Power Criterion, PDA Journal of Pharmaceutical Science & Technology, 54(6): 4780-484 (November/December 2000).	
	CD	Feddah, Majid R. et al., In-Vitro Characterisation of Metered Dose Inhaler Versus Dry Powder Inhaler Glucocorticoid Products: Influence of Inspiratory Flow Rates, J. Pharm. Pharmaceut. Sci. (www.ualberta.ca/~csp) 3(3): 317-324 (2000).	
	CE	Koskela, T. et al., Efficacy of salbutamol via Easyhaler® unaffected by low inspiratory flow, Respiratory Medicine 94: 1229-1233 (December 2000).	
	CF	Nielsen, K.G. et al., Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer®, European Respiratory Journal, 10: 2105-2109 (September 1997).	
	CG	Richards, Robert and Saunders, Michael, Need for a comparative performance standard for dry powder inhalers, Thorax 48: 1186-1187 (November 1993).	
	CH	Ross, Danna L. and Schultz, Robert K., Effect of Inhalation Flow Rate on the Dosing Characteristics of Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI) Products, Journal of Aerosol Medicine, 9: 215-226 (November 2, 1996).	
	CI	Smith, Karen J. et al., Influence of Flow Rate on Aerosol Particle Size Distributions from Pressurized and Breath-Actuated Inhalers, Journal of Aerosol Medicine, 11: 231-245 (November 4, 1998).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Kristen Matter/	Date Considered	02/26/2007
--------------------	------------------	-----------------	------------